IRCT2017092527865N3 IRCT 2017-10-05 Vice chancellor for research, Iran University of Medical Sciences Effect of intravenous (IV) and intra-arterial (IA) autologous bone marrow mononuclear cells (BM-MNCs) in stroke patients. stroke- BM-Mn Cs, cell thrapy The survey and comparison between intravenous (IV) and intra-arterial (IA) autologous bone marrow mononuclear cells (BM-Mn Cs) therapy on the recovery of sub-acute ischemic stroke patients 2017-10-01 anticipated 4 Complete https://irct.ir/trial/22741 interventional Randomization: N/A, Blinding: Single blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 1 Stroke. intravenous (IV) and intra-arterial (IA) autologous bone marrow mononuclear cells (BM-MNCs) in stroke patient..

public Seyed Amir Hosseini

Besides Milad Tower-Hemat Highway-Tehran

Tehran Iran (Islamic Republic of) +98 21 6693 6299 amirhosseini1358@gmail.com Iran University of Medical Sciences scientific Seyed Amir Hosseini

Iran University of Medical Sciences, Besides Milad Tower, Hemat Highway

Tehran Iran (Islamic Republic of) +98 21 6693 6299 amirhosseini1358@gmail.com Iran University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: age range 30–80 years old; time of stroke onset known and treatment could be started within 7 days of onset. If the exact time of stroke is unknown when the symptoms of stroke have been observed to last referred; NIHSS score 8 to20; CT and MRI images can approve stroke; negative pregnancy test in women who are of childbearing age; stroke confined to MCA territory on CT or MRI brain scan; all the study steps detailed to the patient and if the patient's consciousness the patient's relatives have to be explained; signed informed consent if the patient is unable to provide meaningful consent their guardian or legal representative must give their consent to participate by signing the informed consent document. Exclusion criteria: evidence on neuroimaging (CT or MRI) of a brain tumor, cerebral edema with mid line shift and a clinically significant compression of ventricles, cerebellar or brainstem infarction, and intraventricular, intracerebral, or subarachnoid hemorrhage; people who have difficulty accessing them in the future; patients with evidence of life-threatening infection including (AIDS, hepatitis and cancer); renal dysfunction with creatinine .150 mmol/l; before the stroke alone is not able to perform their daily activities; blood glucose levels is not less than 3 mmol or more than 20 mmol; female patients of childbearing potential (unless it is certain that pregnancy is not possible) or breast feeding; patients who are participating in another clinical trial; current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to the study requirements. 30 years 80 years Both I63.5 Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries Treatment - Other intravenous (IV) and intra-arterial (IA) autologous bone marrow mononuclear cells (BM-MNCs) in stroke patient. Score of NIHSS scale. Timepoint: On 2-24 hours,7days,1-3-6-12 month after cell injection. Method of measurement: NIHSS questionnaire (0-42) score. Create Rebleeding. Timepoint: On 2-24 hours, 7days, 1, 3, 6 and 12 months after cell injection. Method of measurement: MRI of brain. MRS score. Timepoint: On 2-24 hours, 7days, 1, 3, 6 and 12 months after cell injection. Method of measurement: MRS questionnair with score 0-6. Rate of Epilepsy. Timepoint: On 24 hours and 7 days after cell injection. Method of measurement: EEG. Evaluation of structural brain by MRI. Timepoint: On 2-24 hours, 7 days, 1, 3, 6 and 12 month after cell injection. Method of measurement: Results of volume of infarction and lateral ventricles before and after cell injection by MRI. Vice chancellor for research, Iran University of Medical Sciences Approved 2016-08-01 Ethics committee of Iran University of Medical Sciences Iran University of Medical Sciences, Besides Milad Tower, Hemat Highway Tehran Iran (Islamic Republic of)